Piper sylvaticum Roxb. is traditionally used by the indigenous people of tropical and\nsubtropical countries like Bangladesh, India, and China for relieving the common cold or a variety\nof chronic diseases, such as asthma, chronic coughing, piles, rheumatic pain, headaches, wounds,\ntuberculosis, indigestion, and dyspepsia. This study tested anxiolytic and antioxidant activities by\nin vivo, in vitro, and in silico experiments for the metabolites extracted (methanol) from the leaves and\nstems of P. sylvaticum (MEPSL and MEPSS). During the anxiolytic evaluation analyzed by elevated\nplus maze and hole board tests, MEPSL and MEPSS (200 and 400 mg/kg, body weight) exhibited a\nsignificant and dose-dependent reduction of anxiety-like behavior in mice. Similarly, mice treated\nwith MEPSL and MEPSS demonstrated dose-dependent increases in locomotion and CNS simulative\neffects in open field test. In addition, both extracts (MEPSL and MEPSS) also showed moderate\nantioxidant activities in DPPH scavenging and ferric reducing power assays compared to the standard,\nascorbic acid. In parallel, previously isolated bioactive compounds from this plant were documented\nand subjected to a molecular docking study to correlate them with the pharmacological outcomes.\nThe selected four major phytocompounds displayed favorable binding affinities to potassium channel\nand xanthine oxidoreductase enzyme targets in molecular docking experiments. Overall, P. sylvaticum\nis bioactive, as is evident through experimental and computational analysis. Further experiments are\nnecessary to evaluate purified novel compounds for the clinical evaluation.
Loading....